| P50 | author | Joel M. Gottesfeld | Q42410767 |
| P2093 | author name string | Massimo Pandolfo | |
| | James R Rusche | |
| P2860 | cites work | The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure | Q24538667 |
| | Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia | Q24634126 |
| | Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing | Q24647477 |
| | DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing | Q59071144 |
| | Breaking the silence in Friedreich's ataxia | Q80286140 |
| | Design of novel histone deacetylase inhibitors | Q80446314 |
| | HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model | Q27301415 |
| | Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex | Q28115394 |
| | Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes | Q28249379 |
| | Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia | Q28250989 |
| | Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion | Q28275699 |
| | Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes | Q28297330 |
| | Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model | Q28472583 |
| | Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model | Q28743986 |
| | Trinucleotide Repeat Disorders | Q29038716 |
| | Chemical phylogenetics of histone deacetylases | Q30977637 |
| | Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription | Q33517116 |
| | The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner | Q33616633 |
| | The clinical development of histone deacetylase inhibitors as targeted anticancer drugs | Q33829390 |
| | Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats | Q33857115 |
| | Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing | Q34019122 |
| | Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells | Q34575655 |
| | Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group | Q34622291 |
| | Iron-sulfur cluster biogenesis and human disease | Q34656661 |
| | A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model | Q35770976 |
| | Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia | Q35865338 |
| | Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation | Q36039174 |
| | Therapeutics development for triplet repeat expansion diseases | Q36277195 |
| | Gene-based approaches toward Friedreich ataxia therapeutics | Q36935359 |
| | DNA triplexes and Friedreich ataxia | Q37062600 |
| | Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia | Q37095593 |
| | Chemical probes for histone-modifying enzymes | Q37272504 |
| | Therapeutic application of histone deacetylase inhibitors for central nervous system disorders | Q37283454 |
| | The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues | Q40149163 |
| | Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. | Q40241487 |
| | Identification of novel isoform-selective inhibitors within class I histone deacetylases | Q40634385 |
| | Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases | Q42109512 |
| | Partial correction of sensitivity to oxidant stress in Friedreich ataxia patient fibroblasts by frataxin-encoding adeno-associated virus and lentivirus vectors | Q45428894 |
| | Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). | Q46817482 |
| | Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo | Q48034382 |
| | Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. | Q55033015 |
| | Frataxin knockin mouse | Q57950173 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Friedreich ataxia | Q913856 |
| P304 | page(s) | 147-154 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia | |
| P478 | volume | 126 Suppl 1 | |